Login
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

veratx.com

What Do They Do?

Develops atacicept and other medicines for serious immunological diseases, including autoimmune kidney diseases and BK virus infections, for patients with those conditions.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −17% (Loss)
vs −$80.3M in Q3 FY2025
  • Aug 10, 2026 TRUTAKNA received FDA accelerated approval and U.S. launch began The company expects the ORIGIN 3 final efficacy analysis in Q3 2026 and a supplemental application in Q4 2026.
  • Jun 2, 2026 FDA agreed to an earlier ORIGIN 3 efficacy analysis plan Results are expected in the third quarter of 2026, with a supplemental application for full approval planned for the fourth quarter of 2026.

Development priorities The older report planned a lupus nephritis trial and delayed resources for it and the BK-virus program; the latest report focuses on completing atacicept’s IgAN development while evaluating further development of the BK-virus program.

Who Do They Compete With?

Competes with Asahi Kasei, Otsuka Pharmaceuticals, Novartis, Travere Therapeutics, Roche, Ionis, Vertex, AstraZeneca, Biogen, Takeda, Arrowhead Pharmaceuticals, BeOne Medicines, Climb Bio, Walden Biosciences, Sanofi, Eli Lilly, Astellas, Boehringer Ingelheim, Memo Therapeutics, and Aurinia Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support